Our Market Access Strategy team delivers insights for informed decision-making and effective navigation of the evolving market access landscape.

Pre-launch
Pre-launch Icon
Launch
Launch Icon
Post-launch
Post-launch Icon

Medical and Commercial Value Assessments

  • Early Phase Due Diligence for Asset Acquisition
  • Medical and Commercial Value Assessments (Early Pipeline To Launch)
  • Market Shaping (PIE Decks and Pre-approval Dossiers)
  • AMCP Dossier and Economic Value Proposition
  • Evidence Generation Plan Gap Assessment
  • Pipeline Asset and Portfolio Assessment (Analogs, Price Bands)

Market Access Commercial Planning

  • Landscape Assessments
  • HUB Vendor RFP and Evaluation, Recommendation and Selection
  • Field Team Engagement Strategy and Planning Tools
  • Environmental Analyses and Business Planning (Across Payer, Patient, Site Of Care, etc.)
  • Annual Strategic Plan Development (including QBR Business Reviews)

Field Execution

  • Payer Engagement Resources
  • Health Economic Models and HEOR Field Tools
  • Payer Conference Engagement Strategy and Messaging
  • HUB and SP Vendor On-boarding, SOW Creation, and Contract Negotiations
  • MA Field and Sales Training

Performance Optimization

  • Evaluate Data and Reporting Needs (from Launch to LOE)
  • KPI Metrics Development
  • Governance and Decision-Making
About

Why Choose Us

Pharmaceutical companies now have a limited number of critical touch points with payers and patients to successfully achieve their reimbursement and product access objectives.

THE VS HEALTH GROUP TEAM ARE EXPERTS IN MARKET ACCESS STRATEGY. THEY WERE AN ASSET TO HELP MITIGATE THE EFFECT OF REIMBURSEMENT CHALLENGES ACROSS OUR PORTFOLIO.

Scott Howell
NOVARTIS
Scroll to Top